investorscraft@gmail.com

Intrinsic value of Aclaris Therapeutics, Inc. (ACRS)

Previous Close$13.47
Intrinsic Value
Upside potential
Previous Close
$13.47

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh2.43 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %4.3NaN
Revenue, $7NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m96NaN
Operating income, $m-90NaN
EBITDA, $m-89NaN
Interest expense (income), $mNaN
Earnings before tax, $m-91NaN
Tax expense, $m0NaN
Net income, $m-91NaN

BALANCE SHEET

Cash and short-term investments, $m191NaN
Total assets, $m251NaN
Adjusted assets (=assets-cash), $m60NaN
Average production assets, $m12NaN
Working capital, $m182NaN
Total debt, $m3NaN
Total liabilities, $m54NaN
Total equity, $m197NaN
Debt-to-equity ratio0.015NaN
Adjusted equity ratio0.111NaN

CASH FLOW

Net income, $m-91NaN
Depreciation, amort., depletion, $m1NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-52NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-0NaN
Free cash flow, $m-52NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m182
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount